

U.S. House Committee on Foreign Affairs
Subcommittee on Africa, Global Health and Human Rights
Global Strategies to Combat the Devastating Health & Economic Impacts of Alzheimer's
Disease

Testimony of Hugh C. Hendrie, MB, ChB, DSc
Professor, Department of Psychiatry
Indiana University School of Medicine
Scientist, Indiana University Center for Aging Research
Scientist, Regenstrief Institute, Inc.

Good afternoon Chairman Smith, Ranking Member Payne and members of the Subcommittee. I appreciate very much being given the opportunity to testify before this committee on the global impact of Alzheimer's disease.

I am Hugh Hendrie, Professor of Psychiatry and Research Scientist at the Center for Aging Research at Indiana University and the original principal investigator for the Indianapolis-Ibadan Dementia project.

Studies that compare the rate of disease in one country to the rate in another country can help us understand the causes of the diseases. The value of these studies is greatly enhanced if they include comparisons from countries with very different environments such as those from the developed and developing worlds where the greater diversity of environmental exposure may make risk factors more identifiable. Alzheimer's disease is likely to be caused by a complicated interaction of genes, environment and toxic exposures. The recent explosion of knowledge about the genetics of Alzheimer's disease and the genetics of human populations now allows for the incorporation of both genetic and environmental information into these comparative studies. The promise of these studies would be to increase our understanding of Alzheimer's disease causation that is applicable to countries throughout the world and to identify risk factors in these countries that are modifiable. Currently there are few such international comparative projects exploring the risk for Alzheimer's disease and fewer still involving African nations. Currently about 70% of all the elderly worldwide are living in developing countries. The burden of caring for Alzheimer Disease patients in these countries is likely to be staggering.

The National Institute on Aging supported Indianapolis-Ibadan dementia project, which is now 20 years old, exemplifies this approach. The project is a longitudinal comparative study of the incidence and prevalence of dementia and Alzheimer's disease and their associated risk factors in 2 elderly community dwelling residents, African Americans residing in Indianapolis Indiana and Yoruba living in Ibadan Nigeria. Over 4000 residents in each community have been evaluated and followed over this period.

An outline of the evolution of the project and its major findings is included below and will be summarized in this brief presentation.

The Evolutionary Path of the Indianapolis-Ibadan Dementia Project

*Hugh C. Hendrie M.B., Ch.B., D.Sc.
Professor, Department of Psychiatry
Indiana University School of Medicine
Scientist, Indiana University Center for Aging Research
Scientist, Regenstrief Institute, Inc.*

INDIANAPOLIS—IBADAN COMPARATIVE EPIDEMIOLOGICAL
STUDY OF ALZHEIMER'S DISEASE

Supported by National Institute of Aging Grant AG09956
and
Alzheimer's Association/F.M. Kirby Foundation
Pilot Research Grant 1R5-95-084

Goals of Comparative Epidemiological Studies

- Compare rates of illness between communities
- Analyze and compare risk factors for the illness
- Benefits of international studies- increase diversity

The First Venture – Dementia Screening Methods: Indian/Non-Indian Manitoba

*Supported by the
National Institute of Aging*

Hypothesis/Objectives for Indian/Non-Indian Study – The Influence of Culture

- Preliminary evidence suggested Alzheimer’s Disease prevalence is low in Canadian Native Americans
- This pilot consisted of a comparative study between elderly Cree (treaty Indian) living on two reserves and non-Indian Winnipeg residents (pilot study)
- Eventual goal to conduct a survey of all elderly treaty Indians primarily Cree and Ojibwa living in Manitoba within and outside reserves

The Role of Ben Osuntokun in the Development of the African Project

The advantages of studying a migrant population

**INDIANAPOLIS – IBADAN
COMPARATIVE EPIDEMIOLOGICAL
STUDY OF ALZHEIMER’S DISEASE**

Supported by National Institute of Aging Grant AG09956
and
Alzheimer’s Association/F.M. Kirby Foundation Pilot Research
Grant IRG-95-084

Phase I – Epidemiology of Dementia/AD 1992 - 2001

- Objective
 - Comparative Study of Migrant Populations – African Americans and Nigerians with similar geographic origins now living in very different environments
 - Compare incidence rates of AD and dementia and their associated risk factors in Yoruba and African-Americans
 - Risk Factors = Classical Epidemiological
 - Demographics
 - Medical Illness
 - Lifestyle Outcomes
 - Outcomes
 - Cognitive Decline
 - Cognitive Impairment not Dementia (multi-domain MCI)
 - Dementia
 - Alzheimer Disease
 - Mortality

IU Center for Aging Research

Phase I – Results

- AD was indeed present in Yoruba. Created major problems for the families but Dementia / AD Rates (Age-standardized overall rate – Dementia - African-Americans 3.24 (2.11-4.38), Yoruba 1.35 (1.13-1.56); AD - African Americans 2.52 (1.40-3.64), Yoruba 1.15 (0.96-1.35) – Lower in Yoruba (but both rates were within the published limits for international studies. No comparative studies in Africa)
- Vascular Risk Frequency * (BMI, Cholesterol levels, Hypertension, Diabetes) – Lower in Yoruba
- Lifestyles Differ by Population

Risk Factors	African Americans	Yoruba
	↑	
Increasing Age	↑	↑
Gender (female)	ns	↑
Low Education	↑	ns
Low Education / Rural Residence	↑	ns
High Social Involvement	↓	↓
Medication		
- Anti-hypertensive	↓	ns

NOTE: ns = not significant, ne = not evaluated
 ↑ Increased Risk ↓ Protection

IU Center for Aging Research

The Genetic Explosion

- Background
 - Population Genetics – Out of Africa
 - Modern humans originated in Africa and spread throughout the world in a series of migratory waves
 - Risk alleles for chronic illnesses distributed throughout the world across populations are likely to have originated in Africa
 - Studies of genetic risk in AD
 - APOE ε4 is a major risk factor for AD in most populations.

IU Center for Aging Research

Phase II – Explore Mechanisms of Dementia/AD - 2001

- Objective / Hypothesis

To build upon our initial findings and intensify our exploration of potential risk factors for dementia/AD by:

- Adding biomarker measurements from blood samples to assess cardiovascular risk and recording vital signs including BP at all visits
- Expanding the genetic studies to include DNA from all consenting participants and analyzing APOE and related genes
- More sophisticated lifestyle assessment
- Enrich population

IU Center for Aging Research

Modeling the Contribution of Genes & Environment

Observed Phenotypic Variation = Genes + Environment +

Genes * Environment + Genes * Genes + Environment * Environment

Models for the nature-nurture construct

Cooper and Kaulman, 1998

IU Center for Aging Research

Biomarker Means and Standard Deviations

	Indianapolis (n=1516)	Ibadan (n=1254)	P-value
	Mean ± SD	Mean ± SD	
Cholesterol (mg/dL)	186.66 ± 40.11	174.51 ± 40.88	<.0001
HDL (mg/dL)	51.23 ± 15.59	50.02 ± 13.79	0.0307
LDL (mg/dL)	112.75 ± 34.51	106.70 ± 33.30	<.0001
Triglycerides (mg/dL)	113.40 ± 55.58	89.47 ± 36.44	<.0001

In 2001 22.3% in Indianapolis on statins
NB Ibadan had higher levels of a measure of oxidative stress

IU Center for Aging Research

United States House of Representatives
Committee on Foreign Affairs

"TRUTH IN TESTIMONY" DISCLOSURE FORM

Clause 2(g) of rule XI of the Rules of the House of Representatives and the Rules of the Committee require the disclosure of the following information. A copy of this form should be attached to your written testimony and will be made publicly available in electronic format, per House Rules.

1. Name: Hugh C. Hendric, MB, ChB, DSc	2. Organization or organizations you are representing: Department of Psychiatry Indiana University School of Medicine Indiana University Center for Aging Research Regenstrief Institute, Inc.
3. Date of Committee hearing: Thursday, June 23, 2011	
4. Have you received any Federal grants or contracts (including any subgrants and subcontracts) since October 1, 2008 related to the subject on which you have been invited to testify? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	5. Have any of the organizations you are representing received any Federal grants or contracts (including any subgrants and subcontracts) since October 1, 2008 related to the subject on which you have been invited to testify? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
6. If you answered yes to either item 4 or 5, please list the source and amount of each grant or contract, and indicate whether the recipient of such grant was you or the organization(s) you are representing. You may list additional grants or contracts on additional sheets. National Institutes on Health/National Institute on Aging Indianapolis/Ibadan Dementia Project Grant R01-AG09956-08 7-1-08 thru 12-31-11 \$659,287 Recipient - IU School of Medicine	
7. Signature: <div style="text-align: center; font-family: cursive; font-size: 1.2em;"> jcb Hendric </div>	

Please attach a copy of this form to your written testimony.